Table 3.
Model | Development | Variables to Input | Patient Population | Prediction of Survival | External Validation |
---|---|---|---|---|---|
PathFx model 1.0 | Forsberg et al. [20], 2011 | Not available | 189 patients treated for metastatic bone disease between 1999 and 2003 | Survival at 1, 3, 6, 12, 18, and 24 months | Forsberg et al. [10], 2012; Piccioli et al. [9], 2015; Forsberg et al. [12], 2017; Ogura et al. [11], 2017; Meares et al. [14], 2019 |
PathFx model 2.0 | Overmann et al. [21], 2020 | Not available | 189 patients treated for metastatic bone disease between 1999 and 2003 | Survival at 1, 3, 6, 12, 18, and 24 months | Overmann et al. [21], 2020 |
PathFx model 3.0 (https://www.pathfx.org) | Anderson et al. [13], 2020 | Age, sex, oncologic diagnosis, pathological fracture, ECOG performance status, hemoglobin level, absolute lymphocyte count, number of skeletal metastases, organ metastases. In case of prostate cancer, PSA, patient age at metastases, treatment, race, comorbidity, alkaline phosphatase velocity. | 208 patients treated for metastatic bone disease between 2015 and 2018 | Survival at 1, 3, 6, 12, 18, and 24 months | Anderson et al. [13], 2020 |
Machine Learning Algorithm (https://sorg-apps.shinyapps.io/extremitymetssurvival/) | Thio et al. [19], 2020 | Age, primary tumor type, visceral metastases, brain metastases, previous systemic therapy, hemoglobin level, white blood cell count, platelet count, absolute lymphocyte count, absolute neutrophil count, albumin level, alkaline phosphatase level, calcium, creatinine, sodium. | 1090 patients treated surgically for long bone metastases between 1999 and 2017 | Survival at 3 and 12 months | None |
SORG Machine Learning Algorithm (https://sorg-apps.shinyapps.io/spinemets/, accessed on 10 July 2021) | Karhade et al. [22], 2018 | White blood cell, albumin, American Society of Anesthesiologist Class, spine location, functional status, hematocrit, alkaline phosphatase. | 1790 patients treated surgically for spinal metastatic disease between 2000 and 2016 | Survival at 1 month | None |
Machine Learning Algorithm (https://sorg-apps.shinyapps.io/spinemetssurvival/, accessed on 10 July 2021) | Karhade et al. [23], 2019 | BMI, other Charlson comorbidity, primary tumor histology, ECOG performance status, ASIA, number of spine metastases, visceral metastases, brain metastases, previous systemic therapy, hemoglobin, platelet, absolute lymphocyte, albumin, alkaline phosphatase, creatinine, INR. | 732 patients treated surgically for spinal metastatic disease between 2000 and 2016 | Survival at 3 and 12 months | None |
ECOG, Eastern Cooperative Oncology Group; PSA, Prostate Specific Antigen; BMI, Body Mass Index; ASIA, American Spinal Injury Association; INR, international normalized ratio.